SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense volatility as investors debate the impact of its new capital framework, which authorizes potential Bitcoin sales to fund debt and share buybacks. The community remains sharply divided between those who view these measures as a necessary evolution for long-term stability and skeptics who fear the dilution signals an unsustainable departure from the firm's core accumulation strategy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors aggressively speculate on potential Russell index rebalancing, driving a surge in volume and intense debate between retail bulls and short sellers. The community remains focused on the company's long-term clinical pipeline and the ongoing battle against heavy short interest.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending as shares rally following the company's announcement of a strategic plan to spin off NBCUniversal and Sky into an independent, publicly traded entity. The community is actively discussing the potential for a rerating of the business as it pivots toward a more streamlined focus, with some traders debating whether the separation sets the stage for future partnerships or acquisitions within the media and connectivity sectors.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is trending amid extreme volatility driven by a major Berkshire Hathaway exit and heavy short interest, while community members actively debate whether the stock is a deep-value opportunity or a failing asset heading for further downside. Investors are closely monitoring its potential for a short squeeze or a strategic merger, despite ongoing concerns over its high debt load and subscriber trends.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors digest its strategic expansion into AI-powered autonomous network infrastructure, highlighted by recent partnerships with major hyperscalers like Google Cloud and Amazon. While some in the community express frustration over recent price volatility and bearish technical patterns, many are highlighting significant insider buying and long-term positioning as a reason to view the current dip as an accumulation opportunity.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending following the acquisition of Iridium Communications, a move investors are interpreting as a strategic shift toward a fully integrated space infrastructure model with recurring revenue potential. While the stock has faced broader sector volatility, the community is actively debating the deal's valuation and the company's long-term ability to compete as a comprehensive space systems provider.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending as investors rotate capital from high-flying tech and AI stocks into the biotech sector, driven by a wave of recent M&A activity, positive clinical data, and expectations of an FDA environment increasingly favorable to innovation. Community sentiment is mixed; while traders are eagerly positioning for potential breakouts and sector-wide rallies, institutional investors remain selective, closely watching clinical trial readouts, patent landscapes, and the impact of sector rotation on overall market stability.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is trending following the FDA approval of Lumvoa, a treatment for thyroid eye disease, with the community closely tracking the company's immediate commercial launch plans and potential for market expansion. Investors are actively debating the stock's valuation, upcoming conference call details, and whether the approval will drive significant long-term growth or lead to profit-taking.

Iridium Communications, Inc. operates as a commercial provider of communications services offering true global coverage, connecting people, organizations and assets to and from anywhere, in real time. It offers its services to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers via satellite network, which has an architecture of operational satellites with in-orbit spares and related ground infrastructure. Its products include personal communicators, messengers, and trackers, satellite phones, push-to-talk-devices, broadband terminals, midband terminals, external antennas, docking stations, apps, accessories and developer tools & resources. The company was founded in 2000 and is headquartered in McLean, VA.

Iridium Communications Inc

Iridium Communications is trending following a definitive agreement to be acquired by Rocket Lab in an $8 billion cash-and-stock deal, a move that community members are highlighting as a major vertical integration play in space infrastructure. Investors are actively discussing the deal's structure, the strategic shift toward satellite connectivity services, and how this acquisition positions Rocket Lab as a more formidable competitor in the space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stifel🏁 $EPRX and said: We initiate coverage of Eupraxia Pharma (EPRX) with a Buy rating, $25 TP. 
$PHAT AZN - AMGN APGE  $BMY  
Here&#39;s what else Stifel had to say in its initiation report: https://x.com/Quantumup1/status/2057195169074847811?s=20

Novice

Stifel🏁 $EPRX and said: We initiate coverage of Eupraxia Pharma (EPRX) with a Buy rating, $25 TP.$PHAT AZN - AMGN APGE $BMY Stifel added-On the back of its Diffusphere platform, Eupraxia is finding a solution to an age-old problem-delivering effective therapies to a precise... https://t.co/MXAF7NEWex

X (Formerly Twitter)

quantumup on X (formerly Twitter): "Stifel🏁 $EPRX and said: We initiate coverage of Eupraxia Pharma (EPRX) with a Buy rating, $25 TP.$PHAT AZN - AMGN APGE $BMY Stifel added-On the back of its Diffusphere platform, Eupraxia is finding a solution to an a...

William Blair🏁 $EPRX and said:::We are initiating coverage of Eupraxia with an Outperform rating and fair value estimate of $14 per share. 
$BMY AZN - AMGN PHAT APGE PFE $CLDX 
Here&#39;s what else William Blair had to say: https://x.com/Quantumup1/status/2036041121407685083?s=20

William Blair🏁 $EPRX and said:::We are initiating coverage of Eupraxia with an Outperform rating and fair value estimate of $14 per share.$BMY AZN - AMGN PHAT APGE PFE $CLDXWilliam Blair added:::Eupraxia is a clinical-stage biotechnology company developing extended-release... https://t.co/c2XeFatxHz

quantumup on X (formerly Twitter): "William Blair🏁 $EPRX and said:::We are initiating coverage of Eupraxia with an Outperform rating and fair value estimate of $14 per share.$BMY AZN - AMGN PHAT APGE PFE $CLDXWilliam Blair added:::Eupraxia is a clinica...

StockTwits Web

Eupraxia Pharmaceuticals Inc

Bristol-Myers Squibb Co.

Celldex Therapeutics Inc.

Quantumup

Phathom Pharmaceuticals Inc

 and said: We initiate coverage of Eupraxia Pharma (EPRX) with a Buy rating, $25 TP. 


  
Here's what else Stifel had to say in its initiation report: 